Guest guest Posted March 23, 2010 Report Share Posted March 23, 2010 From the latest issue of Morningstar Healthcare Observer They want $149.00 for the reportThe latest issue of Morningstar Healthcare Observer is now available. Please click here if you are interested in purchasing the Orphan Drugs Issue (sold a la carte):The March issue focuses on the following topic:Orphan Drugs: From Biotech Niche to Pharma Focus.Focusing on the rare disease market, we provide an overview of the Orphan Drug Act of 1983 and discuss the nature of orphan drug development and commercialization. We analyze the moats in rare disease markets, and why large pharmaceutical firms are increasingly interested in orphan drugs. Finally, we assess what happens when rare disease markets turn competitive, and we offer some case studies.I do not think that I want large pharmaceutical firms to be interested in LDN. Is it possible that they may make minor changes to the chemical and re patented it?Sterling Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.